Ankylosing Spondylitis in Orthopedic Surgery Treatment & Management
- Author: S Craig Humphreys, MD; Chief Editor: Mary Ann E Keenan, MD more...
Medical Care
- No preventive measure or definitive treatment exists for individuals with AS. Early diagnosis and proper patient education are important.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain and decrease inflammation. Aspirin has been reported to have limited benefit. Oral steroids are not used for long-term management of AS because of the high risk of adverse effects.
- Sulfasalazine has been reported to be effective in some patients with peripheral involvement. Sulfasalazine is also useful in patients with coexisting inflammatory bowel disease.
- Laboratory values, including those of ESR and CRP, are used commonly to monitor the progression of the disease and the effectiveness of treatment.
- After identifying persons with extra-articular manifestations, provide proper treatment or refer them to the appropriate specialist. These extra-articular manifestations include acute iritis, aortitis, heart block, pulmonary fibrosis, amyloidosis, and neurologic deficits, including cauda equina.
- Genetic counseling and patient support groups are useful in further educating patients about the disease process and in identifying individuals at increased risk.
Surgical Care
- Surgical treatment is geared toward resolution of the complications related to AS. No curative surgical treatment exists.
- Patients with fusion of the cervical or upper thoracic spine may have significant impairment in line of sight, eating, and psychosocial well-being. These patients may benefit from extension osteotomy of the cervical spine.[25] This procedure is difficult and hazardous; however, if successful, it allows the patient to return to a more functional life.
- Patients with fusion of the spine secondary to AS who report a change in position of the spine should be cautiously treated and should be considered to have sustained a spinal fracture. Surgical intervention may be necessary to stabilize the fracture and prevent neurologic deficit.[26, 27]
- Patients with AS are vulnerable to cervical spine fractures. Long-standing pain may mask the symptoms of fracture. Radiological imaging may fail to identify the fracture due to the distorted anatomy, ossified ligaments, and artifacts. A retrospective case series of 32 patients with AS and cervical spine fractures revealed that in 19 patients (59.4%), a fracture was not identified on plain radiographs. Only 5 patients (15.6%) presented immediately after the injury. Of the 15 patients (46.9%) who were initially neurologically intact, 3 patients had neurological deterioration before admission. Early diagnosis with appropriate radiological investigations may prevent the possible long-term neurological cord damage.[28]
- Note: Patients who develop bowel or bladder dysfunction should be evaluated immediately with MRI to assess for possible cauda equina syndrome secondary to spinal stenosis. The presence of cauda equina syndrome is a surgical emergency requiring decompression within 48 hours to prevent permanent loss of function.
- Patients with significant involvement of the hips may benefit from total hip arthroplasty.[29] Following surgery, heterotropic bone formation can be reduced with use of indomethacin or radiation therapy.
Consultations
- Rheumatologist: Consult a rheumatologist for evaluation and management of ongoing medical treatment of patients with AS. Additional coexisting seronegative spondyloarthropathies can be assessed.
- Gastroenterologist: Refer patients with symptoms suggesting coexisting inflammatory bowel disease to a gastroenterologist for evaluation.
- Cardiologist: Refer patients with cardiac involvement, including aortitis or heart block, to a cardiologist for evaluation.
- Physical therapist or physical medicine and rehabilitation specialist: Refer all patients to a physical therapist or rehabilitation specialist. Symptoms of AS are worse with inactivity and are relieved with exercise. As a result, a proper exercise program is a crucial element of treatment.
- Geneticist: Patients may be referred for genetic counseling to assess questions regarding the probabilities of relatives developing the disease.
- Support groups: Many patients benefit from various support groups, which can provide further education on the disease process and available treatment options.
Diet
- Generally, no dietary restrictions are implemented for patients with AS; however, patients with coexisting diseases, such as inflammatory bowel disease, have dietary restrictions.
Activity
- A proper exercise program is a crucial component in the treatment of AS. Patients obtain a significant reduction in symptoms following exercising. Referral to physical therapy or to a rehabilitation specialist is useful in assisting patients to develop an appropriate exercise program.[30, 31]
Cawley MI, Chalmers TM, Ball J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis. Sep 1971;30(5):539-40. [Medline]. [Full Text].
Hanson JA, Mirza S. Predisposition for spinal fracture in ankylosing spondylitis. AJR Am J Roentgenol. Jan 2000;174(1):150. [Medline]. [Full Text].
Hunter T. The spinal complications of ankylosing spondylitis. Semin Arthritis Rheum. Dec 1989;19(3):172-82. [Medline].
Sutherland RI, Matheson D. Inflammatory involvement of vertebrae in ankylosing spondylitis. J Rheumatol. Sep 1975;2(3):296-302. [Medline].
van der Linden S, van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol. Jul 2000;12(4):263-8. [Medline].
van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. Nov 1998;24(4):663-76, vii. [Medline].
Alvarez I, López de Castro JA. HLA-B27 and immunogenetics of spondyloarthropathies. Curr Opin Rheumatol. Jul 2000;12(4):248-53. [Medline].
McGonagle D, Emery P. Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis. J Rheumatol. Oct 2000;27(10):2302-4. [Medline].
Muñoz-Villanueva MC, Muñoz-Gomariz E, Escudero-Contreras A, Pèrez-Guijo V, Collantes-Estévez E. Biological and clinical markers of disease activity in ankylosing spondylitis [letter]. J Rheumatol. Dec 2003;30(12):2729-32. [Medline]. [Full Text].
Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A. Management of reactive arthritis. Expert Opin Pharmacother. Jan 2004;5(1):61-70. [Medline].
O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis. Jun 1992;51(6):705-6. [Medline]. [Full Text].
O'Shea FD, Riarh R, Anton A, Inman RD. Assessing Back Pain: Does the Oswestry Disability Questionnaire Accurately Measure Function in Ankylosing Spondylitis?. J Rheumatol. Apr 15 2010;[Medline].
Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol. Mar 1996;23(3):487-90. [Medline].
Mengshoel AM, Førre O. Pain and fatigue in patients with rheumatic disorders. Clin Rheumatol. Dec 1993;12(4):515-21. [Medline].
Ringsdal VS, Helin P. Ankylosing spondylitis--education, employment and invalidity. Dan Med Bull. Jun 1991;38(3):282-4. [Medline].
Wordsworth BP, Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol. May 1986;25(2):175-80. [Medline].
McGuigan LE, Hart HH, Gow PJ, Kidd BL, Grigor RR, Moore TE. Employment in ankylosing spondylitis. Ann Rheum Dis. Aug 1984;43(4):604-6. [Medline]. [Full Text].
Lehtinen K. Working ability of 76 patients with ankylosing spondylitis. Scand J Rheumatol. 1981;10(4):263-5. [Medline].
Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). May 5 2010;[Medline].
Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol. Apr 2010;37(4):835-41. [Medline].
Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol. Apr 1999;26(4):966-70. [Medline].
Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. Apr 1999;26(4):971-4. [Medline].
Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. May 2008;75(3):291-4. [Medline].
van der Heijde D, Spoorenberg A. Plain radiographs as an outcome measure in ankylosing spondylitis. J Rheumatol. Apr 1999;26(4):985-7. [Medline].
Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis. Jul 1999;58(7):399-406. [Medline]. [Full Text].
Halm H, Metz-Stavenhagen P, Zielke K. Results of surgical correction of kyphotic deformities of the spine in ankylosing spondylitis on the basis of the modified arthritis impact measurement scales. Spine. Jul 15 1995;20(14):1612-9. [Medline].
Hunter T, Dubo HI. Spinal fractures complicating ankylosing spondylitis. A long-term followup study. Arthritis Rheum. Jun 1983;26(6):751-9. [Medline].
Anwar F, Al-Khayer A, Joseph G, Fraser MH, Jigajinni MV, Allan DB. Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J. Mar 2011;20(3):403-7. [Medline].
Shih LY, Chen TH, Lo WH, Yang DJ. Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup. J Rheumatol. Sep 1995;22(9):1704-9. [Medline].
Hidding A, van der Linden S, Gielen X, et al. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res. Jun 1994;7(2):90-6. [Medline].
Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol. Feb 1990;17(2):228-33. [Medline].
Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. Mar 2008;67(3):323-9. [Medline]. [Full Text].
Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford). Apr 1 2010;[Medline].
Inman RD, Maksymowych WP. A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis. J Rheumatol. Mar 15 2010;[Medline].
Rasker JJ, Prevo RL, Lanting PJ. Spondylodiscitis in ankylosing spondylitis, inflammation or trauma? A description of six cases. Scand J Rheumatol. 1996;25(1):52-7. [Medline].
Dihlmann W, Delling G. Discovertebral destructive lesions (so called Andersson lesions) associated with ankylosing spondylitis. Skel Radiol. 1978;3:10-6.
Agarwal AK, Reidbord HE, Kraus DR, Eisenbeis CH Jr. Variable histopathology of discovertebral lesion (spondylodiscitis) of ankylosing spondylitis. Clin Exp Rheumatol. Jan-Feb 1990;8(1):67-9. [Medline].
Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. Nov 1998;24(4):737-51, viii. [Medline].
Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. Feb 1983;26(2):186-90. [Medline].
Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. Jul 1997;36(7):766-71. [Medline]. [Full Text].
Guillemin F, Briançon S, Pourel J, Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum. Jul 1990;33(7):1001-6. [Medline].
Bakker C, van der Linden S, van Santen-Hoeufft M, Bolwijn P, Hidding A. Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol. Jul 1995;22(7):1304-10. [Medline].
Bennett PH, Burch TA, eds. Population Studies of the Rheumatic Diseases. Amsterdam, The Netherlands: Excerpta Medical Foundation; 1968:456-537.
Calin A, Elswood J, Rigg S, Skevington SM. Ankylosing spondylitis--an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol. Aug 1988;15(8):1234-8. [Medline].
Calin A, Nakache JP, Gueguen A, et al. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. J Rheumatol. Apr 1999;26(4):975-9. [Medline].
Dunn N, Preston B, Jones KL. Unexplained acute backache in longstanding ankylosing spondylitis. Br Med J (Clin Res Ed). Dec 7 1985;291(6509):1632-4. [Medline]. [Full Text].
Eck JC, Humphreys SC. Diagnosis and treatment of common metabolic spinal disorders in the geriatric population. South Med J. Dec 1998;91(12):1090-7. [Medline].
Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. May 2008;67(5):620-4. [Medline].
George B, Gauthier N, Lot G. Multisegmental cervical spondylotic myelopathy and radiculopathy treated by multilevel oblique corpectomies without fusion. Neurosurgery. Jan 1999;44(1):81-90. [Medline].
Gossec L, Dougados M, Phillips C, et al, for the ASAS (ASsessment in AS) International Working Group. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis. Jun 2008;67(6):782-8. [Medline]. [Full Text].
Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. Nov 2008;58(11):3402-12. [Medline].
Resnick D, Niwayama G. Discovertebral destruction in a man with chronic back problems. Invest Radiol. Mar-Apr 1981;16(2):89-94. [Medline].
Wang F, Yan CG, Xiang HY, Xing T, Wang NS. The significance of platelet activation in ankylosing spondylitis. Clin Rheumatol. Jun 2008;27(6):767-9. [Medline].
Ward MM. Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am. Nov 1998;24(4):815-27, x. [Medline].
Wordsworth BP, Pearcy MJ, Mowat AG. In-patient regime for the treatment of ankylosing spondylitis: an appraisal of improvement in spinal mobility and the effects of corticotrophin. Br J Rheumatol. Feb 1984;23(1):39-43. [Medline].

